Description
TB-500 Fragment 17–23 is a synthetic seven-amino-acid peptide (LKKTETQ) corresponding to the central actin-binding motif within the parent Thymosin Beta-4 sequence. This region has been characterized in published research as the functional “active core” responsible for much of the actin-sequestering activity of full-length TB-500 (Tβ4), without the larger flanking regions. The fragment is investigated in preclinical research as a streamlined research tool for studying actin polymerization dynamics, cell migration, angiogenesis, and tissue repair signaling — with a significantly smaller molecular size (~847 Da vs ~4963 Da for full Tβ4) that may offer different pharmacokinetic and absorption characteristics. TB-500 Fragment 17–23 is studied as a comparator and structural analog for understanding the minimum functional sequence required for β-thymosin biological activity.
Benefits (Research Focus)
• Actin-binding motif — studied as the minimal functional sequence within the parent Thymosin Beta-4 (Tβ4) actin-sequestering region
• Cell migration research — investigated for cytoskeletal reorganization activity at significantly reduced peptide size
• Angiogenesis — explored for new blood vessel formation endpoints in healing tissue models
• Tissue recovery models — examined for wound closure and regenerative signaling in preclinical research
• Inflammation modulation — researched for balanced inflammatory and reparative pathway endpoints
What Researchers Look At
• Comparative actin-binding activity between Fragment 17-23 (LKKTETQ) and full-length Tβ4
• Cytoskeletal reorganization, F-actin / G-actin dynamics in cell-based assays
• Angiogenesis markers (VEGF, integrins) in endothelial cell migration research
• Wound closure rates in corneal, dermal, and ischemic injury preclinical models
• Minimum functional sequence research and structure-activity relationship (SAR) studies
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 10 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: TB-500 Fragment 17–23
• Synonyms: Tβ4 Fragment 17-23; LKKTETQ; Thymosin Beta-4 actin-binding motif; Tβ4(17-23)
• Class: β-thymosin fragment; actin-binding heptapeptide; 7 amino acids
• Sequence: Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ)
• Formula / M.W.: C36H66N10O13, ~846.98 g/mol (per COA; verify exact MW against batch spec)
• Parent compound: Thymosin Beta-4 (Tβ4) — positions 17–23 of full 43-amino-acid sequence
• CAS: 476014-70-7
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• TB-500 Fragment 17-23 VPeptide Canada — November 12, 2025
• TB-500 Fragment 17-23 VPeptide Canada — July 1, 2026 – Batch# TBF06-0710
This product has Sterility Testing
• TB-500 Fragment 17-23 VPeptide Canada — July 14, 2026 – Batch# TBF06-0710
